Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
Maria Pepe, Giovanni Bartolucci, Ilaria Marcelli, et al.
Brain Sciences (2023) Vol. 13, Iss. 10, pp. 1494-1494
Open Access | Times Cited: 10

Showing 10 citing articles:

Ketamine treatment for anhedonia in unipolar and bipolar depression: a systematic review
Aleksander Kwaśny, Julia Kwaśna, Alina Wilkowska, et al.
European Neuropsychopharmacology (2024) Vol. 86, pp. 20-34
Closed Access | Times Cited: 4
Effect of intravenous esketamine on postoperative sleep disturbance, anxiety, and depression in elderly patients undergoing laparoscopic abdominal surgery: a randomized controlled trial
Haijin Wang, Lan Wang, Jing Gao, et al.
BMC Geriatrics (2025) Vol. 25, Iss. 1
Open Access
Esketamine Nasal Spray Compassionate Use Program in the Netherlands: an open Label, Multi-Center Cohort Study in Severe Treatment-Resistant Depression
Abel Busz, Emma Schmidt, Rob van den Brink, et al.
Journal of Affective Disorders Reports (2025), pp. 100905-100905
Open Access
Baseline monocyte count predicts symptom improvement during intravenous ketamine therapy in treatment-resistant depression: a single-arm open-label observational study
Bruno Pedraz‐Petrozzi, Moritz Spangemacher, Anton Deicher, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 2
Heart Rate Variability as a Potential Predictor of Response to Intranasal Esketamine in Patients with Treatment-Resistant Depression: A Preliminary Report
Lorenzo Moccia, Giovanni Bartolucci, Maria Pepe, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4767-4767
Open Access | Times Cited: 2
Patient and provider perspectives on the phenomenon and effective treatment of treatment-resistant depression: A grounded theory
Aubrey Bornhoff, Edward B. Davis, Jonathon Yousey, et al.
Journal of Affective Disorders Reports (2024) Vol. 16, pp. 100779-100779
Open Access | Times Cited: 1
A Multi-Center, Open-Label, Single-Arm Study to Investigate the Early Effectiveness of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Using a Mobile Self-Monitoring Application
Junhyung Kim, Seung‐Hoon Lee, Cheolmin Shin, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 9, pp. 1143-1143
Open Access
Intranasal Esketamine for Patients with Major Depressive Disorder: A Systematic Review and Meta-Analysis
Soroush Oraee, Mohammadreza Alinejadfard, Hossein Golsorkh, et al.
Journal of Psychiatric Research (2024) Vol. 180, pp. 371-379
Closed Access
Effects of Ketamine and Esketamine on Cognitive Functions in Treatment-Resistant Depression
Mahir Mutlu, Çağrı Öven, Bilge Sena Kurt, et al.
Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry (2024) Vol. 17, Iss. 3, pp. 493-506
Open Access
Repeated Intravenous Infusions of Esketamine in Inpatients with Bipolar Depression: A Retrospective Real-World Study
Norah J. Shire, Michael Ioannou, Örjan Falk, et al.
Journal of Affective Disorders Reports (2024) Vol. 19, pp. 100870-100870
Open Access
Page 1

Scroll to top